Brokerage Firm Rating on Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited (TEVA) : 17 analysts are covering Teva Pharmaceutical Industries Limited (TEVA) and their average rating on the stock is 1.68, which is read as a Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Teva Pharmaceutical Industries Limited (TEVA) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Teva Pharmaceutical Industries Limited (TEVA) : The highest short term price target forecast on Teva Pharmaceutical Industries Limited (TEVA) is $100 and the lowest target price is $55. A total of 16 equity analysts are currently covering the company. The average price of all the analysts is $73.05 with a standard deviation of $9.98.


For the current week, the company shares have a recommendation consensus of Buy. Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $53.02 and $52.84 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $53.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $53.42, notching a gain of 1.54% for the day. The total traded volume was 5,859,819 . The stock had closed at $52.61 on the previous day.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.